A SMARTER GREEK

A SMARTER GREEK
Send Message
View as an RSS Feed
  • AbbVie Is Well Poised For Continued Outperformance  [View article]
    You never know J n J although late just might like more of it. ( Imbruvica) and the rest of the Abbv complete package. Before the merger PCYC announced joint projects with 3 major pharma's adding imbruvica to their solutions for solid tumors . Also I'm curious as to how their pancreatic cancer program is doing and their other joint projects. The release of updated data at the next national Oncology conference or before then,could be quite exciting!
    Dec 15, 2015. 09:17 AM | Likes Like |Link to Comment
  • Buy AbbVie Inc. For Both The Dividend And Growth  [View article]
    Thank you.
    But once this first line approval is in place, and Imbruvia does start to be used instead of the lethal chemo, what if anyone knows will be the estimated increase of sales to ABBV in addittion to the current quarterly increase of sales of Imbruvica?
    Dec 9, 2015. 07:41 AM | Likes Like |Link to Comment
  • Buy AbbVie Inc. For Both The Dividend And Growth  [View article]
    Has anyone or do you have the increased sales forecast from Imbruvica once it does get 1st line approval ( hopefully soon) ...and even more important replaces "Chemo" as 1st line on just the leukemia types it is already approved for sale for now?

    A goal of this company from the beginning was to create product that not only prolongs and saves lives but also elliminates that which is the quite often terminator the Chemo treatments.
    Dec 8, 2015. 12:40 PM | 5 Likes Like |Link to Comment
  • AbbVie Is Well Poised For Continued Outperformance  [View article]
    Imbruvica will replace chemo in many situations and thus prolong and save more lives! It is truly a blockbuster. That was one of the major goals of the COB of Pcyc! I'm looking forward to see the results of Imbruvica with the use of other products with their current partners and solid tumors! Trying to figure out future numbers based on those results actually are too astronomical to figure at this point! Also the work that is in progress on pancreatic cancer!? Well I guess we shall see in the not too decent future! Best investment ABBV has made! I still feel that more JnJ comes to this conclusion with and via Jansen might propel them to get even more involved!
    Nov 13, 2015. 11:07 AM | Likes Like |Link to Comment
  • AbbVie Is Well Poised For Continued Outperformance  [View article]
    Today will be a good buying opportunity especially after all this Fed talk and looking forward to the huge and important Oncology Annual Conference in early December! Updates on Imbruvica should be major!
    Nov 12, 2015. 09:15 AM | Likes Like |Link to Comment
  • AbbVie Is Well Poised For Continued Outperformance  [View article]
    Alex,
    We are probably cousins! That was my Mom's maiden name and I was made in Cyprus. I Was Snr VP Painewebber and then Pru.... 30+ years. We should talk. My office # is 201-5685551.
    I know and very good friends with the ex CEO/Chrm of PCYC and prior created ISRG! for over 25 years.
    I am most excited about Imbruvica and the ongoing test they have going in joint research with them especially with solid tumors.... and the potential it adds to ABBVIE Makes it even more attractive for a merger?! Smart of J n J swallows!
    Lets talk!
    Nov 10, 2015. 10:48 AM | Likes Like |Link to Comment
  • After Hours Gainers / Losers  [View news story]
    Any good data / prediction on DXCM earnings and or WWAV. /? Make my life easier I hope!
    Aug 5, 2015. 08:15 AM | Likes Like |Link to Comment
  • AbbVie: Is There Enough Time To Promote New Drugs Before Humira Patent Expired?  [View article]
    Good morning! Has anyone looked at the potential and the current state of PCYC's R/A innovation? If you do it just might prove very exciting with a huge potential.
    I'm waiting for the Amreican National Oncology Conference later this month in Philly, where hopefully there will be more updates on PCYC partnerships re: Solid tumors. Plus their quareterly report usually by 2nd week of May. Financials and more updates.
    Apr 7, 2015. 08:07 AM | 2 Likes Like |Link to Comment
  • AbbVie: Is There Enough Time To Promote New Drugs Before Humira Patent Expired?  [View article]
    $Aabv& $PCYC 2 weeks ago FDA gave go ahead to Phase2 for PCYC new R/A drug based on preliminary results. Hey maybe they have another blockbuster and J & J does not have a piece of this baby! Might this be another reason ABBV was highest bidder?
    Smarter Greek
    Check it out, most analyst have missed this. Also hopefully by 4th quarter PCYC might be getting 1st Line use approval from FDA for Imbruvica applied for past May! That should rocket sales even further! Well done ABBV and PCYC!
    Apr 3, 2015. 10:38 AM | Likes Like |Link to Comment
  • Pharmacyclics: Is A $19 Billion Valuation Reasonable?  [View article]
    Check out the late friday press releases. Re; Colon and Tumor preliminary results with their partners! Un believable. results! PCYC will become a main add on and block buster also used with other products. ( very smart!) Also FDA gave go ahead with further Phase testing on their new R/A product based on preliminary testing......All that can add huge and further potential.
    Feb 28, 2015. 04:04 PM | 1 Like Like |Link to Comment
  • Pharmacyclics Announces Presentation of Phase III and Long Term Follow Up Data on IMBRUVICA™ in Chronic Lymphocytic Leukemia (CLL) at ASCO 
    Once this makes it through, this is the Holy Grail for a new fast/safe. and effective handling of blood cancers! Just the beginning!
    Apr 22, 2014. 07:10 AM | Likes Like
  • "Not cheap" Pharmacyclics is headed higher on Ibrutinib potential: JPMorgan  [View news story]
    tremendous move! Great product saving and prolonging life, with much less if any bad side effects!
    Bob Duggan the CEO/Chrmn has done this before. ISRG at 12 up to
    500+ now at 350.
    Same guy, great visionary that gets things done! Always first with new technology that works and changes the field.
    Sep 26, 2013. 12:24 PM | 2 Likes Like |Link to Comment
  • Pharmacyclics (PCYC) submits an NDA for ibrutinib (developed with JNJ's Janssen) for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. The drug has Breakthrough Therapy designation for both indications and is a major catalyst for the shares. This is one to watch closely given the takeout chatter around ONXX. In other company news, Jesse McGreivy is promoted to Chief Medical Officer.  [View news story]

    Great news ahead of schedule! Remember CEO/Chrm of this baby was also very insturmental with launching ISRG and got involved at $12.00! now over $450 and billions in sales.

    He is smart and cares a lot about helping others!
    Jul 10, 2013. 08:09 AM | Likes Like |Link to Comment
  • Pharmacyclics (PCYC) submits an NDA for ibrutinib (developed with JNJ's Janssen) for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. The drug has Breakthrough Therapy designation for both indications and is a major catalyst for the shares. This is one to watch closely given the takeout chatter around ONXX. In other company news, Jesse McGreivy is promoted to Chief Medical Officer.  [View news story]
    Ahead of schedule! Nice....remember CEO/Chrmn of this company is same person that launched the technology responsible for and thus ISRG for 12 to 450+. His involvement was at $12.00
    He is a smart dude and good guy who cares a lot for others!
    Jul 10, 2013. 08:07 AM | Likes Like |Link to Comment
  • Pharmacyclics (PCYC +9.5%) trades higher today after RBC Capital ups the shares to Outperform and raises its price target to $100 from $70. The firm cites optimism over a number of upcoming catalysts for its leukemia drug Ibrutnib, which is being jointly developed by PCYC and JNJ's Janssen Pharmaceuticals.  [View news story]
    Mr. Duggan the CEO and Chairman..is repeating again with a phenominlal product(s), and successfull company in PCYC as he did
    with ISRG..from 12 to 500!
    Real company, great products, good management..de ja vu!
    May 13, 2013. 01:17 PM | 1 Like Like |Link to Comment
COMMENTS STATS
26 Comments
11 Likes